Clinicopathological characteristics and survival analysis of different molecular subtypes of breast invasive ductal carcinoma achieving pathological complete response through neoadjuvant chemotherapy
Patients with invasive ductal carcinoma of different molecular subtypes exhibit varying prognoses after achieving pCR to neoadjuvant chemotherapy. Those in the HR + /HER-2- group are younger, have a higher lymph node stage, and the lowest OS and CSS, whereas patients in the HR + /HER-2 + group have the highest OS and CSS.
Authors
- Yao Guo (ORCID: https://orcid.org/0000-0001-6312-6987)
- Junyan Li (ORCID: https://orcid.org/0000-0002-3737-9339)
- Yang Xu (ORCID: https://orcid.org/0009-0001-7788-0398)
- Cheng Xiao (ORCID: https://orcid.org/0000-0002-7014-2405)
- Junhua Huang
Institutions
- Chengdu Fifth People's Hospital (CN)
Publication Details
- Journal
- World Journal of Surgical Oncology
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1186/s12957-024-03535-x
- Citations
- 1
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.29